Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...
Zacks.com on MSN29d
Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?Sales of the influenza vaccine, Fluarix, rose 14%. Sales of Established vaccines improved 8%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine co-developed in ...
A second group of adults aged 50 to 64 received mRNA-1083 or GSK’s influenza vaccine Fluarix, once again given alongside Spikevax. mRNA-1083 consists of components of mRNA-1010, Moderna’s ...
Fluarixâ„¢, GlaxoSmithKline Vaccines) in primed and unprimed cohorts of children aged from 18 to 47 months. The main aim of the study was to assess the non-inferiority of HI antibody responses ...
Engerix-B (GlaxoSmithKline) 72 hr Manufacturer Immune globulin (human) Gamastan S/D (Bayer) Cumulative exposure for 7 days Manufacturer Influenza virus vaccine Fluarix (GlaxoSmithKline ...
The other brands containing thiomersal are Fluarix by GlaxoSmithKline, Influvac by Solvay Health Care and Agrippal by Wyeth. Mercury-free flu jab brands available on the NHS are Begrivac from ...
It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best ADR stocks. American Depositary Receipts (ADR) are US-listed securities that represent shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback